Clinical trials
Marginal Zone B Cell Lymphoma clinical trials
Below are recruiting marginal zone b cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 134 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT06919939RecruitingPhase 2
Epcoritamab and Loncastuximab for relapsed large B-cell lymphoma
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Miami, FloridaAges 18 years+ - NCT03869619Recruiting
Real-life data study for adults with recent lymphoma
This study collects “real-world” health information about adults whose lymphoma was diagnosed within the last 6 months. It aims to better understand lymphoma types and how patients do over time, using data from everyday care rather than testing a new drug.
ArrasAges 18 years+ - NCT04670029RecruitingPhase 3
Testing an APA program to improve outcomes in large B-cell lymphoma
This Phase 3 trial studies whether an APA program (an added supportive program during care) can improve event-free survival for people with diffuse large B-cell lymphoma. It may help by supporting patients during standard first-line treatment so they do better over time.
BesançonAges 65 years+ - NCT05846750RecruitingPhase 2
Obinutuzumab plus lenalidomide for relapsed marginal zone lymphoma
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Tianjin, TianAges 18 years+ - NCT06180174RecruitingPhase 1
CD19-targeted CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07862010RecruitingEarly Phase 1
Study of GI001 for B-cell lymphoma and leukemia that has returned or not responded
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
Yunnan, KunmingAges 18–75 - NCT06321289RecruitingPhase 1/Phase 2
Donor T cell therapy for B-cell lymphoma
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Beijing, Beijing MunicipalityAges 18–75 - NCT06454968RecruitingPhase 2
Combination therapy for first-line marginal zone lymphoma
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06461182RecruitingPhase 2
PET Scan Test for Slow-Growing Lymphoma
This trial uses a special PET scan to take detailed pictures of slow-growing lymphomas, likely before or after your regular treatment scan. It may help your doctor see exactly where the lymphoma is in your body.
Taipei, BeitouAges 20–100 - NCT06503276RecruitingPhase 2
Orelabrutinib and radiation for a type of eye lymphoma
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06478472Recruiting
Orelabrutinib plus rituximab for marginal zone lymphoma
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
Xiamen, FujianAges 18 years+ - NCT07774572RecruitingPhase 1
Circular RNA study for B-cell blood cancers
This study looks at a new way to treat B-cell blood cancers that have not responded to other treatments or have come back. It tests a therapy that targets cancer cells using RNA, which is a molecule that helps make proteins in your body.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07775508RecruitingPhase 1
Car t cell therapy for relapsed or refractory b cell lymphoma
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
BeijingAges 18–75 - NCT07763210RecruitingPhase 2
IT therapy for immune cell-related side effects after CAR T
This trial tests a new way to give treatment directly into the spinal fluid for a serious side effect of CAR T cell therapy called ICANS. It may help people with certain types of lymphoma who are getting standard CAR T therapy and experience this brain-related complication.
Nashville, TennesseeAges 18 years+ - NCT07691606RecruitingPhase 1
Testing a new drug for B-cell lymphoma that has come back
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
Los Angeles, CaliforniaAges 18 years+ - NCT06678282Recruiting
Testing an investigational cell therapy for B-cell lymphoma or leukemia
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
Zhenzhou, HenanAges 18–75 - NCT04834024RecruitingPhase 3
MIL62 plus lenalidomide vs lenalidomide alone for rituximab-refractory lymphoma
This trial tests whether adding MIL62 to lenalidomide works better than lenalidomide alone in people with follicular lymphoma that no longer responds to rituximab. The goal is to improve tumor control by using an additional medicine along with standard treatment.
BeijingAges 18 years+ - NCT04110301RecruitingPhase 1/Phase 2
MIL62 plus lenalidomide for relapsed follicular or MZ lymphoma
This early-stage study tests whether MIL62 combined with lenalidomide can shrink or control follicular lymphoma or marginal zone (MZ) lymphoma that has come back or not responded to earlier treatment. It’s designed for adults with measurable disease and enough body strength to take part.
BeijingAges 18 years+ - NCT07583810RecruitingPhase 2
Nemtabrutinib and Rituximab for Marginal Zone Lymphoma
This trial tests a combination of two drugs—nemtabrutinib (a BTK inhibitor that targets cancer cells) and rituximab (an antibody drug)—to treat marginal zone lymphoma, a type of blood cancer. The study aims to see if this combination works better than standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT07548697RecruitingEarly Phase 1
Safety study of CT1182 for relapsed B-cell lymphoma
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
Wuhan, HubeiAges 18–75 - NCT07502118RecruitingPhase 2/Phase 3
NexCAR19 for B-cell blood cancers that came back
This trial tests NexCAR19 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma or B-cell acute lymphoblastic leukemia that didn't respond to or came back after other treatments. It aims to see if this therapy can help control the cancer.
AnkaraAges 18 years+ - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79
Hear when a new Marginal Zone B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for marginal zone b cell lymphoma?
- Yes. Clin2 currently lists 134 recruiting marginal zone b cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a marginal zone b cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a marginal zone b cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.